Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determination of the Protective Efficacy of the PvCS/Montanide ISA-51 Vaccine Formulation Against Controlled Infection With Plasmodium Vivax Sporozoites

NCT07373301 is registered in ClinicalTrials.gov with Malaria Vaccine and Drug Development Center as lead sponsor.

NCT NCT07373301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07373301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determination of the Protective Efficacy of the PvCS/Montanide ISA-51 Vaccine Formulation Against Controlled Infection With Plasmodium Vivax Sporozoites
Lead sponsor
Malaria Vaccine and Drug Development Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 19, 2026
Completion date
June 12, 2028
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria prevention, plasmodium vivax infection, plasmodium vivax malaria